Can Cipla challenge the dominance of GSK's Advair?
This article was originally published in Scrip
A generic challenge to GlaxoSmithKline's top-selling asthma drug, Advair (fluticasone plus salmeterol), may be on the way, with India's Cipla claiming that its generic product offers "identical activity" to Advair and that its delivery system could match GSK's Diskus, the intricate device through which the combination is inhaled.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.